ARQT — Arcutis Biotherapeutics, Inc.
$31.20-3.11%
Last close: · regular session
After-hours $31.20 0.00% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ARQT in the TickerWise workspace.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 342
- Website: https://www.arcutis.com
Latest SEC filings for ARQT
Latest ARQT news
- Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026 Read article
- Arcutis Biotherapeutics advances 11% to new 52-week high Read article
- Arcutis jumps as Cantor issues new Overweight citing lead product Read article
- Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical Read article
- Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award Read article
- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rated “Moderate Buy” by Wall Street Brokerages Read article
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.